GC Cell Corp
KOSDAQ:144510
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
17 120
27 500
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
G
|
GC Cell Corp
KOSDAQ:144510
|
333.6B KRW |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
385.9B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.6B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.7B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.7B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
48.8B USD |
Loading...
|
Market Distribution
| Min | -163 055.6% |
| 30th Percentile | -2.2% |
| Median | 2.7% |
| 70th Percentile | 6.8% |
| Max | 22 874.8% |
Other Profitability Ratios
GC Cell Corp
Glance View
GC Cell Corp. engages in the research and development of cell curing agents and in the transport and sale of consignment inspection samples. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2016-06-23. The firm operates its business through four segments. The Specimen Testing Service segment provides sample testing services, clinical trial services, and veterinary testing services. The Cell Therapy segment is engaged in cell culture and technology transfer business. The Cord Blood Storage segment is engaged in the cord blood storage business. The Other Business segment is engaged in bio-logistics business and others.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for GC Cell Corp is -39.3%, which is below its 3-year median of -4.9%.
Over the last 3 years, GC Cell Corp’s Operating Margin has decreased from 27.3% to -39.3%. During this period, it reached a low of -39.3% on Oct 30, 2025 and a high of 27.3% on Aug 30, 2022.